Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rocio D Murphy"'
Autor:
Yaru Shi, Katrina M. Nolan, Robert L. Burton, Tulin Shekar, Rocio D. Murphy, Natalie Banniettis, Luwy Musey, Ulrike K. Buchwald
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Pneumococcal serogroups consist of structurally related serotypes, and serotype-specific antibodies can cross-react against other serotypes within the same serogroup. Cross-reactivity of vaccine-induced serotype 6A antibodies, and, to a lesser extent
Externí odkaz:
https://doaj.org/article/67c29386504f4f9c9be3b03037d0927c
Autor:
Gowrisankar Rajam, Yuhua Zhang, Joseph M. Antonello, Rebecca J. Grant-Klein, Lauren Cook, Reshma Panemangalore, Huy Pham, Stephanie Cooper, Thomas D. Steinmetz, Jennifer Nguyen, Mathias W. Pletz, Grit Barten-Neiner, Rocio D. Murphy, Leonard J. Rubinstein, Katrina M. Nolan
Publikováno v:
mSphere, Vol 7, Iss 4 (2022)
ABSTRACT Streptococcus pneumoniae is a major cause of community-acquired pneumonia (CAP) in young children, older adults, and those with immunocompromised status. Since the introduction of pneumococcal vaccines, the burden of invasive pneumococcal di
Externí odkaz:
https://doaj.org/article/54c92dbec88d43e1b1ac8f0c54ada833
Autor:
Joseph M. Antonello, Rebecca Greway, Tina Green, Polly De Gorguette D'Argoeuves, Adrienne H Howlett, Yuhua Zhang, Cyrille J Bonhomme, Katrina M. Nolan, Rocio D Murphy, David Goldblatt
Publikováno v:
Bioanalysis. 12:1363-1375
Aim: To re-optimize the pneumococcal (Pn) electrochemiluminescence (ECL) assay and to validate and bridge the enhanced assay to the WHO ELISA, to support the Phase III clinical trial program for V114, a 15-valent Pn conjugate vaccine. Materials & met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee427d50cc414a25552a53a65f37b5c
https://doi.org/10.4155/bio-2020-0023
https://doi.org/10.4155/bio-2020-0023
Autor:
Katrina M. Nolan, Tina Green, Rocio D Murphy, Marie E Bonhomme, Joseph M. Antonello, Christina J Schier
Publikováno v:
Bioanalysis. 12(14)
Background: To streamline and improve throughput, the agar-based multiplexed opsonophagocytic killing assay (MOPA) was optimized and validated on a microcolony platform for use in the Phase III clinical trial program for V114, an MSD 15-valent pneumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96c5336bd635b3fa46c08a2fe077285
https://pubmed.ncbi.nlm.nih.gov/32686954
https://pubmed.ncbi.nlm.nih.gov/32686954